Source: Insight on the News, July 1, 1996 v12 n25 p39(1). Title: DEA (Drug Enforcement Agency) restless about Ritalin: doctors sounding the alarm about a popular drug used to combat attention disorders in kids. Author: Joyce Price Abstract: Ritalin is a stimulant and its side effects have been noted. The consumption of Ritalin in the US went from 6 mil prescriptions in 1993 to 10.5 mil in 1995. About 2 mil children from ages 5-12 received the drug as a control for ADHD during this time period. Drug abuse by teens has also been noted. Doctors are sounding the alarm about a popular drug used to combat attention disorders in kids. The use of Ritalin has soared 500 percent in the United States during the last five years and a growing number of doctors worry that the drug is being overprescribed. According to Los Angeles pediatrician Lawrence H. Diller, the number of Americans taking the drug doubled to 2.6 million between 1993 and 1995. Most of them -- about 2 million -- are children ages 5 through 12 who take Ritalin for attention deficit/hyperactivity disorder, or ADHD, a condition marked by inattention, impulsive behavior and, in some cases, hyperactivity. Ritalin, a stimulant whose generic name is methylphenidate, is related to amphetamine and methamphetamine and is regulated by the Drug Enforcement Administration, or DEA, in the same category as cocaine, morphine, PCP, codeine and methadone. "There has been a tremendous increase in consumption and prescription of Ritalin," says Itzhak Frank, a pediatric neurologist at North Shore University Hospital in New York, "and I can join the statement that not every child who is restless needs to get Ritalin automatically." Both Diller and Frank note that ADHD is a "behavioral" diagnosis, not one based upon a blood 1 test or X-ray. Because of that, a physician may prescribe a medication "rather than addressing the thornier and more time-consuming issues of emotions, family relationships or school environment," says Diller, who sounded the alarm in an article in the Hastings Center Report, a publication that examines ethical issues in medicine. The DEA and the U.N. International Narcotics Control Board agree there is cause for concern about methylphenidate. "The documentation ... directly refutes the assertions that methylphenidate is a benign, mild stimulant that is not associated with abuse or serious side effects," stated the DEA in a recent report on the drug. It cited 1993 U.N. statistics that found that the United States "produces and consumes five times more methylphenidate than the rest of the world combined." The agency also referred to evidence of methylphenidate abuse, particularly among adolescents: "Recent trends indicate that adolescents are giving and selling their prescription medications, and youngsters are crushing the tablets and snorting the powder like cocaine." Side effects of methylphenidate can include "dose-related increases in blood pressure, heart rate, respiration and body temperature, appetite suppression and increased alertness," according to the DEA. "Weight loss and growth retardation are common side effects of chronic methylphenidate pharmacotherapy in youngsters, although drug holidays on weekends and/or summers can usually compensate for these deficits. Serious side effects include facial tics and muscle twitching." Abuse of methylphenidate can lead to "psychotic episodes, violent behavior, tolerance and severe psychological dependence." Methylphenidate should be one part of a "multimodal" treatment that includes remedial psychological, educational and social measures, says the DEA. "While most practitioners subscribe to such a multimodal approach to the treatment of ADHD, most children are prescribed methylphenidate chronically as their sole treatment." Full Text COPYRIGHT 1996 Washington Times Corporation